Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Augusto Blacker Miller, a controversial figure from Peru's Fujimori era, has died in a Rio de Janeiro prison hospital. The 80-year-old, arrested in Brazil last December on an Interpol warrant, succumbed to cardiorespiratory arrest, reigniting debates about justice, aging detainees, and cross-border legal accountability.
As the AI infrastructure race accelerates, Nvidia's relentless innovation cycle and commanding market position point to sustained growth, with data center spending projected to reach trillions annually by 2030.
The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.
The MOLT token, inspired by the AI-exclusive social platform Moltbook, skyrocketed to a $93M valuation before a dramatic crash, highlighting the volatile and speculative nature of event-driven memecoins.
As tech giants scramble to curb soaring AI costs, a strategic pivot toward custom silicon is reshaping the competitive landscape, with Broadcom's design prowess and TSMC's manufacturing dominance creating a powerful new axis of influence.
A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.
Qatar has tripled its flagship venture capital fund to $3 billion, adding a strategic sweetener: subsidized access to AI computing power. The move aims to position Doha as a competitive hub for tech talent and deep-tech startups in the Gulf region.
The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.
In the shadow of tech giants, two quantum computing specialists, IonQ and D-Wave Quantum, are vying for investor attention with distinct approaches to AI. While both remain speculative bets, a closer look at their technology, finances, and market position reveals one as a potentially less volatile choice for those venturing into this frontier.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
Facing internal resistance to AI adoption, payments company MassPay linked its use directly to a profit-sharing pool. The result, according to CEO Ran Grushkowsky, was not just significant cost savings and eliminated hiring needs, but a notable boost in team morale.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Russian forces have reportedly seized the settlement of Prydorozhnie in southeastern Ukraine's Zaporizhzhia region, according to a defense ministry statement. The claim, yet to be independently verified, marks the latest in a series of incremental territorial gains.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.
